Related Experiment Video

Updated: May 28, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

Padmanee Sharma1, Klaus Wagner, Jedd D Wolchok

  • 1Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Box 0018-7, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.

Nature Reviews. Cancer
|October 25, 2011
PubMed

Insights

Two new immunotherapies, sipuleucel-T and ipilimumab, offer survival benefits for advanced prostate cancer and melanoma. Further research is needed to understand their mechanisms and optimize patient response through biomarkers and combination therapies.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • The US Food and Drug Administration (FDA) approved sipuleucel-T and ipilimumab for advanced cancers.
  • These novel immunotherapy agents demonstrate a survival benefit in metastatic prostate cancer and melanoma, respectively.
  • The precise mechanisms underlying their clinical efficacy remain largely unknown.

Purpose of the Study:

  • To elucidate the mechanisms of action for sipuleucel-T and ipilimumab.
  • To identify biomarkers distinguishing treatment responders from non-responders.
  • To guide future research in cancer immunotherapy.

Main Methods:

  • The study is a review and discussion of current knowledge and future directions.
  • Focuses on understanding immune responses and tumor biology.
  • Proposes strategies for immune monitoring and clinical endpoint assessment.

Main Results:

  • Sipuleucel-T and ipilimumab have shown a survival advantage in specific metastatic cancers.
  • Understanding the mechanisms is critical for optimizing immunotherapy.
  • Key areas for advancement include biomarker discovery and combination therapies.

Conclusions:

  • Further investigation into the mechanisms of novel immunotherapies is essential.
  • Development of immune-monitoring strategies and biomarkers is a priority.
  • Evaluating combination therapies is crucial for enhancing clinical benefits in cancer treatment.

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...